Compositions and methods for visualizing tissue under illumination with near-infrared radiation, including compounds comprising near-infrared, closed chain, sulfo-cyanine dyes and prostate specific membrane antigen ligands are disclosed.

Methods of preparing fluorinated compounds by carboxylative fluorination using fluoride are contained herein. Fluorinated compounds are provided. Methods of using fluorinated compounds are contained herein.

Compounds that inhibit histone (HDACI) and/or activate Nrf2 and HIF, and compositions containing the same are disclosed. Methods of treating diseases and conditions wherein inhibition of HDAC and/or activation of Nrf2 and HIF provide a benefit, like a cancer, a neurodegenerative disorder, a peripheral neuropathy, a neurological disease, traumatic brain injury, stroke, hypertension, malaria, an autoimmune disease, autism, autism spectrum disorders, and inflammation, also are disclosed.

Disclosed herein, inter alia, are compounds and methods for G-protein-coupled receptor 44 detection.

Described are compounds for the binding of S1PR2, and imaging agents and pharmaceutical compositions including said compounds. Also described are methods employing the compounds, imaging agents, and pharmaceutical compositions. These methods include imaging and/or treatment of diseases associated with S1PR2.

The present invention is directed to the use of radiolabeled ligands of leukocyte function-associated antigen1 (LFA1) receptor in order to image and quantify leukocyte activation, recruitment and in vivo trafficking of tumor infiltrating lymphocytes. Diagnostic methods and methods of monitoring cancer therapy, including immunotherapy represent embodiments of the present invention.

The subject matter of the invention is PSMA inhibitor-HYNIC derivatives of PSMA-L.sub.1-L.sub.2-HYNIC formula, aromatic and aliphatic hydrazone derivatives, a radiopharmaceutical kit for 99mTc isotope labelling, radiopharmaceutical preparation and its application for prostate cancer and its metastasis diagnostics.

A device for synthesizing a radiotracer includes a microfluidic chip having a concentration module configured to concentrate and capture a radioactive reagent from a radioactive regent mixture, a reaction chamber in fluidic communication with the concentration module and configured to synthesize a radiotracer by reaction of the concentrated radioactive reagent and a radiotracer precursor therein, and a purification module in fluidic communication with the reactor chamber and configured to purify the synthesized radiotracer. The device also includes a heating means positioned in relation to the microfluidic chip for heating the microfluidic chip during evaporation and reaction; and a first valve fluidically coupled with the concentration module and the reaction chamber and a second valve fluidically coupled with the reaction chamber and the purification module for operably controlling transit of various substances or mixtures among the concentration module, the reaction chamber and the purification module.

A method for removing or controlling or quantifying the presence of aldehydes, in particular acetaldehyde, is described. Such a method is useful in prolonging the shelf life of a pharmaceutical product.

Disclosed is a composite amphiphilic peptide nanomicelle, the preparation method and application, as to a novel integrin .sub.v.sub.3-targeted amphiphilic peptide nanomicelles, the applications in fluorescence imaging, photodynamic therapy, sonodynamic therapy and combined treatments. Based on the prominent properties of integrin .sub.v.sub.3-targeted amphiphilic peptide nanomicelles such as great biocompability, fluorescence imaging of encapsulated materials, photodynamic therapy and photothermal therapy, it is promising to be widely used in the field of labeling and tracing in vivo, biomedical imaging, early detection and treatment for tumor. It has good economic and social benefits in terms of life health and personalized medicine.